<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="11229"><DrugName>MOR-102</DrugName><DrugSynonyms><Name><Value>MOR-102</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ICAM-1 antibody (inflammation), MorphoSys</Value></Name></DrugSynonyms><CompanyOriginator id="21404">MorphoSys AG</CompanyOriginator><CompaniesSecondary><Company id="21404">MorphoSys AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="11229" type="Drug"><TargetEntity id="318502" type="siDrug">MOR-102</TargetEntity></SourceEntity><SourceEntity id="21404" type="Company"><TargetEntity id="4295869785" type="organizationId">MorphoSys AG</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"/><TargetEntity id="10037153" type="MEDDRA"/><TargetEntity id="D011565" type="MeSH"/><TargetEntity id="-1735788310" type="omicsDisease"/><TargetEntity id="490" type="siCondition"/></SourceEntity><SourceEntity id="5224" type="Action"><TargetEntity id="772" type="Mechanism">Anti-ICAM-1 (CD54) Agents</TargetEntity><TargetEntity id="1292" type="Mechanism">LFA-1/ICAM-1 Interaction Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="PTGT-00400" type="ciTarget"><TargetEntity id="181872199733833" type="siTarget">Intercellular adhesion molecule 1</TargetEntity><TargetEntity id="2728" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication><Indication id="281">Psoriasis</Indication></IndicationsSecondary><ActionsPrimary><Action id="5224">ICAM-1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="15184">Systemic antipsoriatic product</Action><Action id="1596">Immunomodulator</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="538">Humanized antibody</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-28T12:24:53.000Z</LastModificationDate><ChangeDateLast>2009-03-31T12:33:14.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="21404" linkType="Company"&gt;MorphoSys&lt;/ulink&gt; was investigating MOR-102, a humanized IgG antibody (generated using its HuCAL technology) directed against intercellular adhesion molecule-1 (ICAM-1), for the potential treatment of inflammatory disorders, including psoriasis [&lt;ulink linkID="448837" linkType="reference"&gt;448837&lt;/ulink&gt;], [&lt;ulink linkID="457518" linkType="reference"&gt;457518&lt;/ulink&gt;]. In April 2002, MorphoSys anticipated MOR-102 entering clinical trials in 2004 [&lt;ulink linkID="448837" linkType="reference"&gt;448837&lt;/ulink&gt;], [&lt;ulink linkID="457518" linkType="reference"&gt;457518&lt;/ulink&gt;]; in June 2005, preclinical studies were ongoing [&lt;ulink linkID="610064" linkType="Reference"&gt;610064&lt;/ulink&gt;]. In mid-2002, MorphoSys was seeking to outlicense the compound for further development beyond phase II, and for the marketing of any end product [&lt;ulink linkID="465343" linkType="reference"&gt;465343&lt;/ulink&gt;], [&lt;ulink linkID="457518" linkType="reference"&gt;457518&lt;/ulink&gt;].  In February 2006, the company discontinued  development in order to focus its resources on &lt;ulink linkID="53625" linkType="Drug"&gt;MOR-103&lt;/ulink&gt; (qv) [&lt;ulink linkID="652329" linkType="Reference"&gt;652329&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2005, the company released preclinical results that showed MOR-102 was no more effective than placebo at healing psoriasis in a mouse model. The company had aimed to compare MOR-102's efficacy against &lt;ulink linkID="6808" linkType="Drug"&gt;alefacept&lt;/ulink&gt; and &lt;ulink linkID="11578" linkType="Drug"&gt;efalizumab&lt;/ulink&gt;. However, spontaneous healing in the negative placebo group meant it was impossible to discriminate between compound-mediated healing and placebo-mediated healing. The company said that there was no clear explanation for the difference from an earlier successful trial other than the variability between skin grafts originating from different patients. It planned to continue development of the compound despite the study's inconclusivity [&lt;ulink linkID="598881" linkType="Reference"&gt;598881&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2003, preclinical data on MOR-102 were presented at the 10th Human Antibodies and Hybridomas conference in Osaka, Japan. MOR-102 administered 10 mg/kg given every other day greatly reduced measures of psoriasis in a xenotransplant model of human psoriatic skin on to nude mice. The compound reduced all measures of psoriatic injury [&lt;ulink linkID="509794" linkType="reference"&gt;509794&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2003, preclinical data on MOR-102 were presented at the Drug Discovery Technology meeting in Boston, MA. In a cell-protein binding assay measuring binding of SKW3 cells to immobilized ICAM-1, MOR-102 inhibited cell binding with IC50 values ranging from 3 to 11 nM, in comparison to 2 nM for &lt;ulink linkID="2533" linkType="Drug"&gt;enlimomab&lt;/ulink&gt; [&lt;ulink linkID="504688" linkType="reference"&gt;504688&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In February 2003, MorphoSys and &lt;ulink linkID="22546" linkType="Company"&gt;Boehringer Ingelheim&lt;/ulink&gt; entered a therapeutic antibody collaboration and cross license agreement, in which MorphoSys was to receive an exclusive worldwide license to patents owned or controlled by Boehringer. MorphoSys was to develop, make and sell therapeutic and diagnostic antibodies targeting the ICAM-1 molecule. In return, Boehringer was to receive exclusive commercial licenses to therapeutic antibodies against two undisclosed targets, which MorphoSys would generate utilizing its HuCAL GOLD antibody technology [&lt;ulink linkID="479823" linkType="reference"&gt;479823&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="21404">MorphoSys AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication><StatusDate>2006-02-24T00:00:00.000Z</StatusDate><Source id="652329" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21404">MorphoSys AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2006-02-24T00:00:00.000Z</StatusDate><Source id="652329" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="21404">MorphoSys AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2002-04-23T00:00:00.000Z</StatusDate><Source id="448837" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21404">MorphoSys AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2002-04-23T00:00:00.000Z</StatusDate><Source id="448837" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00400"><Name>ICAM-1</Name><SwissprotNumbers><Swissprot>P05362</Swissprot><Swissprot>P13597</Swissprot><Swissprot>P33729</Swissprot><Swissprot>Q00238</Swissprot><Swissprot>Q28806</Swissprot><Swissprot>Q5NKV4</Swissprot><Swissprot>Q5NKV6</Swissprot><Swissprot>Q5NKV9</Swissprot><Swissprot>Q95132</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14881">Boehringer Ingelheim International GmbH</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21404">MorphoSys AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="1">Drug - Discovery/Design</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="110600" title="Boehringer and MorphoSys to enter therapeutic antibody collaboration and cross license agreement       "/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>